<DOC>
	<DOCNO>NCT00393146</DOCNO>
	<brief_summary>This study design look safety , tolerability effectiveness 28 day dose GW856553 rheumatoid arthritis patient .</brief_summary>
	<brief_title>A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : The subject male female ≥ 18 year age . To eligible , female subject must negative pregnancy test ( i.e . serum beta hCG test ) : 1. nonchildbearing potential ( i.e . physiologically incapable become pregnant ) . This include female postmenopausal . For purpose study , post menopausal define amenorrhoeic great 2 year appropriate clinical profile , e.g . age appropriate , history vasomotor symptom . Postmenopausal status confirm serum FSH oestradiol concentration screen . Surgical sterility define female hysterectomy and/or bilateral oophorectomy tubal ligation . OR 2. childbearing potential agrees commit one protocolapproved method contraception detail Section 7.1 . Body weight ≥ 50 kg ( 110lbs ) male ≥ 45 kg ( 99lbs ) female . Body mass index ( BMI ) within range 18.535.0 kg/m2 inclusive . The subject diagnosis RA accord revised 1987 criterion American College Rheumatology ( ACR ) ( see Appendix 6 ) . The subject must DAS28 ≥ 4.2 ( DAS28 calculate use ESR ) . The subject must liver function ( ALT , AST total bilirubin ) test &lt; 1.5 x ULN screen . The subject must ALP &lt; 2 x ULN screen . The subject must normal serum folate level screen ( folate supplement administer required must stable 4 week prior randomisation ) . The subject able understand comply protocol requirement , instruction protocolstated restriction . Signed date write informed consent prior admission study . Exclusion criterion : The subject three month prior history regular alcohol consumption exceed average weekly intake &gt; 21 unit ( average daily intake great 3 unit ) male , average weekly intake &gt; 14 unit ( average daily intake great 2 unit ) female . 1 unit equivalent halfpint ( 284mL ) beer/lager ; 25mL measure spirit 125mL wine ; positive alcohol breath test screen visit . The subject history liver disease . The subject positive Hepatitis B surface antigen Hepatitis C antibody result within 3 month start study . The subject history elevate liver function test one occasion ( ALT , AST , total bilirubin &gt; 2 x ULN ALP &gt; 3 x ULN ) past 7 month . The subject currently receive biological antirheumatic therapy . The subject fail one antiTNFα biological therapy due lack efficacy . The subject receive antirheumatic biological therapy within 6 month ( i.v . administered therapy long halflives e.g . infliximab ) 3 month ( subcutaneously administer therapy iv administer therapy short halflives e.g . adalimumab etanercept ) prior randomisation . The subject receive rituximab . The subject use oral prednisolone dose &gt; 10mg/day , methotrexate &gt; 25 mg/week sulphasalazine &gt; 5g/day . The subject 's DMARD dose regimen change 4 week prior randomisation . The subject 's current DMARD regimen change significantly ( i.e . likely impact disease activity study period ) within 3 month prior dose e.g . addition DMARD , change dose great 2.5mg methotrexate . The subject receive leflunomide less 6 month prior randomisation . The subject fail 3 DMARDs . The subject 's NSAIDs , COX2 inhibitor glucocorticoid dose regimen change time four week prior randomisation . The subject 's statin dose regimen change significantly 3 month prior randomisation The subject significant cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition , opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . The subject acute infection history repeat chronic infection . The subject history active tuberculosis . The subject history malignancy , except surgically cure basal cell carcinoma female cure cervical carcinoma ( &gt; 2 yrs prior ) . The subject history HIV immunosuppressive disease . The subject participate clinical trial within 3 month prior study onset nonbiological therapy ; within 6 month biological therapy . The subject Hb &lt; 9 g/dL platelet count &lt; 150 000/mm3 . The subject calculate creatinine clearance less 60mL/min ( subject calculate creatinine clearance ≥ 50mL/min &lt; 60mL/min may still include consultation GSK medical monitor , eligible gadolinium enhancement MRI scan ) . The subject uncontrolled diabetes psoriasis . The subject joint injection glucocorticoid within previous 4 week . The subject pregnant nursing . The subject receive medication opinion investigator and/or GSK medical monitor , would interfere study procedure , objective compromise subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>MRI</keyword>
</DOC>